Pharmafile Logo
Pharmafocus logo
Advanced Search

agreement

Showing 6 posts of 6 posts found.

handshake_2

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement

May 14, 2025
Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement

Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …

News

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant

May 6, 2025
Mergers and Acquisitions (OTC & VMS), Clayton, Clayton Dubilier & Rice (CD&R), Corporate, M&A, Opella, Sanofi, agreement

Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofi’s …

News

HIV vaccine candidate successfully optimised for industrial production

October 30, 2024
Research and Development HIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement

Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise …

News

ViroCell Biologics signs Master Services Agreement with NCI-designated cancer centre

July 23, 2024
Business Services Cancer, Oncology, ViroCell Biologics, agreement

ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer …

News
money_pills_2

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

May 20, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …

News
ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016
Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …

News
The Gateway to Local Adoption Series

Latest content

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

November 27, 2025

InnotiveDx gets £1m grant to advance UTI diagnostics system

November 27, 2025

Cellbyte raises $2.75m to fund pharma drug launch platform

November 27, 2025

Accession Therapeutics doses first patient in new cancer immunotherapy trial

November 26, 2025

ViVac Pharma appoints Keren Leshem as CEO

November 26, 2025